{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=76",
    "query": {
      "intervention": "Single Dose Placebo",
      "page": 76
    },
    "page_size": 10
  },
  "pagination": {
    "page": 76,
    "page_size": 10,
    "total_count": 4633,
    "total_pages": 464,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=77&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=75&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T02:52:28.464Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01393223",
      "title": "Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Cystitis"
      ],
      "interventions": [
        {
          "name": "LP-08 80mg",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        },
        {
          "name": "LP-08 20mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lipella Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 21,
      "start_date": "2015-07-21",
      "completion_date": "2018-06-14",
      "has_results": false,
      "last_update_posted_date": "2018-11-01",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01393223"
    },
    {
      "nct_id": "NCT02044094",
      "title": "Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "buprenorphine and naloxone",
          "type": "DRUG"
        },
        {
          "name": "hydromorphone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 39,
      "start_date": "2013-11",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2018-04-24",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02044094"
    },
    {
      "nct_id": "NCT05773794",
      "title": "Scavenging of Reactive Carbonyl Species by Dietary Flavonoids in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Human Health",
        "Reactive Carbonyl Species",
        "Polyphenols"
      ],
      "interventions": [
        {
          "name": "Soymilk, green tea, or blueberry",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control group",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "North Carolina Agriculture & Technical State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "25 Years to 70 Years"
      },
      "enrollment_count": 48,
      "start_date": "2023-02-06",
      "completion_date": "2023-12-19",
      "has_results": true,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 1,
      "location_summary": "Kannapolis, North Carolina",
      "locations": [
        {
          "city": "Kannapolis",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05773794"
    },
    {
      "nct_id": "NCT00528879",
      "title": "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 915,
      "start_date": "2007-09",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2015-10-20",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 28,
      "location_summary": "Tempe, Arizona • Encino, California • Fresno, California + 24 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00528879"
    },
    {
      "nct_id": "NCT00048542",
      "title": "Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Juvenile Idiopathic"
      ],
      "interventions": [
        {
          "name": "Double-Blind Adalimumab/Placebo + MTX",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Double-Blind Adalimumab/Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "OLE BSA Adalimumab +/- MTX",
          "type": "DRUG"
        },
        {
          "name": "OLE FD Adalimumab +/- MTX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Years to 17 Years"
      },
      "enrollment_count": 171,
      "start_date": "2002-09",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2011-08-22",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048542"
    },
    {
      "nct_id": "NCT00461370",
      "title": "Safety Study of SRX251 Capsules in Healthy Female Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "SRX251",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Azevan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2007-04",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2008-03-13",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00461370"
    },
    {
      "nct_id": "NCT03943056",
      "title": "A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "BIIB091",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2019-05-13",
      "completion_date": "2020-01-10",
      "has_results": false,
      "last_update_posted_date": "2021-03-22",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03943056"
    },
    {
      "nct_id": "NCT01563445",
      "title": "Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Intracerebral Haemorrhage"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2001-11",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01563445"
    },
    {
      "nct_id": "NCT00615966",
      "title": "Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Diannexin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alavita Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 58,
      "start_date": "2008-02",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2011-06-29",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 5,
      "location_summary": "Baltimore, Maryland • Livingston, New Jersey • New York, New York + 2 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Livingston",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00615966"
    },
    {
      "nct_id": "NCT04294966",
      "title": "Age-Related Effects of THC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Tolerance",
        "Adolescent Behavior",
        "THC"
      ],
      "interventions": [
        {
          "name": "Dextrose",
          "type": "DRUG"
        },
        {
          "name": "Dronabinol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-03-10",
      "completion_date": "2021-05-01",
      "has_results": true,
      "last_update_posted_date": "2023-11-09",
      "last_synced_at": "2026-11-19T02:52:28.464Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04294966"
    }
  ]
}